David Burgoyne, Ph.D.Founder and CEO
Dr. David Burgoyne has over 20 years of experience in the business of drug discovery and early stage pharmaceutical development. Trained as a marine natural products chemist, David obtained his Ph.D. from the University of British Columbia in 1992 for his studies on Pacific Ocean marine sponges. This research led to the discovery of Contignasterol, a marine natural product with anti-inflammatory properties. For this and subsequent research, he was awarded the Science Council of BC Young Innovator award in 2000. Starting from 1997, David held executive positions at Inflazyme Pharmaceuticals, first as VP Research serving as a key contributor to teams which advanced multiple products from discovery to clinical development, and then as VP Business Development, where his experience included licensing, mergers and acquisitions. David founded Naegis in 2009 recognizing that serious inflammatory diseases in our aging population remain a critical health problem in need of novel solutions.